This company listing is no longer active
ProMIS Neurosciences Management
Management criteria checks 2/4
ProMIS Neurosciences' CEO is Gail Farfel, appointed in Sep 2022, they has a tenure of less than a year. Their total yearly compensation is $1.02M , comprised of 14.2% salary and 85.8% bonuses, including company stock and options. They directly owns 0.023% of the company’s shares, worth CA$12.00K. The average tenure of the management team and the board of directors is 3.7 years and 5.3 years respectively.
Key information
Gail Farfel
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 14.18% |
| CEO tenure | less than a year |
| CEO ownership | 0.02% |
| Management average tenure | 3.7yrs |
| Board average tenure | 5.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$21m |
| Dec 31 2022 | US$1m | US$144k | -US$18m |
Compensation vs Market: Gail's total compensation ($USD1.02M) is above average for companies of similar size in the Canadian market ($USD184.46K).
Compensation vs Earnings: Insufficient data to compare Gail's compensation with company performance.
CEO
Gail Farfel (59 yo)
less than a year
Tenure
US$1,017,163
Compensation
Dr. Gail M. Farfel, Ph D., serves as Chief Executive Officer of ProMIS Neurosciences, Inc. since September 19, 2022 and serves as its Director from June 29, 2023. She serves as Director at AVROBIO, Inc. si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 8.1yrs | US$683.14k | 1.86% CA$ 959.6k | |
| CEO & Director | less than a year | US$1.02m | 0.023% CA$ 12.0k | |
| Founder | 19.2yrs | US$577.72k | 1.22% CA$ 625.7k | |
| Chief Operating Officer | 1.8yrs | US$413.49k | 0% CA$ 0 | |
| Chief Financial Officer | 6.3yrs | US$142.40k | 0.068% CA$ 35.1k | |
| Chief Development Officer | 7yrs | US$525.57k | 0.074% CA$ 37.9k | |
| Head of Pharmacology/Toxicology & Senior Consultant | 5.3yrs | no data | no data | |
| Chief Physics Officer | 2.2yrs | no data | no data | |
| Head of Manufacturing & Senior Consultant | no data | no data | no data | |
| Chief Medical Officer | 1.3yrs | no data | no data |
3.7yrs
Average Tenure
64yo
Average Age
Experienced Management: PMN's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Chairman | 8.1yrs | US$683.14k | 1.86% CA$ 959.6k | |
| CEO & Director | less than a year | US$1.02m | 0.023% CA$ 12.0k | |
| Founder | 16.5yrs | US$577.72k | 1.22% CA$ 625.7k | |
| Member of Business Advisory Board | 4.4yrs | no data | no data | |
| Independent Director | 9.3yrs | US$40.00k | 0.73% CA$ 377.6k | |
| Member of Business Advisory Board | no data | no data | no data | |
| Chair of Scientific Advisory Board | 4.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.1yrs | no data | no data | |
| Independent Director | 2.2yrs | US$40.00k | 0% CA$ 0 | |
| Independent Director | 8.1yrs | US$40.00k | 0.91% CA$ 468.6k | |
| Member of Scientific Advisory Board | 5.3yrs | no data | no data | |
| Lead Independent Director | 1.8yrs | US$40.00k | 0% CA$ 0 |
5.3yrs
Average Tenure
64yo
Average Age
Experienced Board: PMN's board of directors are considered experienced (5.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/25 16:07 |
| End of Day Share Price | 2023/07/21 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ProMIS Neurosciences, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Francis Edward Hickman | Guggenheim Securities, LLC |
| Douglas Loe | Leede Financial Inc |